Skip to main content
Premium Trial:

Request an Annual Quote

Research and Markets RNAi -- Technologies, Markets, and Companies Report

Premium

Research and Markets recently released its latest RNAi report.

The report, entitled RNAi — Technologies, Markets, and Companies, estimates the market for RNAi reagents to be about $300 million, a figure predicted to grow to $400 million next year and $850 million by 2010.

The report also includes profiles of 75 companies using the techno-logy, as well as their collaborations.

Chapters of the report focus on such topics as alternative RNA splicing, antisense oligonucleotides, ribozymes, locked nucleic acids, RNAi mechanisms, peptide nucleic acids, and historical landmarks in the development of RNAi.

Details about obtaining the report can be found at http://www.researchandmarkets.com/reports/42874/.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.